12:45 – 2 pm
Saturday, September 7

Expert Discussion: A Closer Look at a Treatment Option for Pediatric Immune Thrombocytopenia (SY2)

This non-CE symposium will feature a discussion on the use of Nplate, a recently-approved TPO-receptor agonist for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP). The discussion will include two pediatric case studies.

Amgen Homepage

APHON thanks Amgen. for their generous support of this event.

Executive Ballroom
Allison Imahiyerobo, NP
12 – 1:15 pm
Thursday, September 5

Meet the Challenges of Post-HSCT VOD: An Interactive Case Study of a 1-Year-Old Male With Neuroblastoma (SY1)

Join us as we review a case study involving a pediatric patient with neuroblastoma who was at risk for and subsequently developed veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome, following hematopoietic stem-cell transplantation. This case study highlights the patient’s history of present illness and gives a detailed, post-HSCT review of the VOD progression, management and supportive care approaches, and the differential diagnosis. Current VOD diagnostic criteria will also be discussed.

Please note that while this optional event is included in the conference fee, selecting the event on the registration form is required to attend. Space is limited. 


APHON thanks Jazz Pharmaceuticals, Inc. for their generous support of this event.

Executive Ballroom
Rita Secola, PhD RN FAAN
Laura Vasquez, BSN RN CPON®
7:30 – 8:45 am

Recognition Breakfast for Certified Oncology Nurses: Inspired Nurse (RB)

19 1CNE Nursing is one of the few professions that affords one the opportunity to impact lives on such a profound level, not only physically but emotionally and spiritually as well. Yet the same qualities that make nursing so deeply rewarding can also make it a challenge, over time, to sustain your energy and passion. Whether on the frontlines of direct patient care or in any part of the Nursing spectrum we all need to feel attached to the “why” of our work.  

Rich Bluni, RN
9–9:30 am
Friday, September, 6

Evolving Treatment Landscape for Primary Hemophagocytic Lymphohistiocytosis

Primary hemophagocytic lymphohistiocytosis (HLH) is an ultra-rare, rapidly progressive, often-fatal syndrome of hyperinflammation where hyperproduction of interferon gamma may drive immune system hyperactivation, ultimately leading to multiple organ failures. The immediate goal of treatment is to quickly control the hyperinflammation and to prepare for hematopoietic stem cell transplantation.


Exhibit Hall Theater